Alzheimer's Association campaigns for broader Leqembi coverage: report

After the Centers for Medicare & Medicaid Services (CMS) slapped down a recent petition for wider coverage of Eisai and Biogen’s new drug Leqembi, the Alzheimer’s Association is digging its heels in.

The lobbying group is mobilizing hundreds of people diagnosed with or caring for someone with the debilitating neurodegenerative disease as part of a grassroots campaign to press Medicare for early access to Leqembi (lecanemab) plus other potential Alzheimer’s drugs in the amyloid-clearing class.